Sun, Jan 25, 2015, 5:51 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

PDL BioPharma, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • MCROC43 MCROC43 Apr 18, 2000 10:19 AM Flag

    BIG NEWS???

    Well, even if its just made up, let us in on your hot news. Please.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • try to stay away from negative earning

      Wall street warn us few weeks ago and they
      warn us
      again yesterday and early today.

      you should
      watch Bloomberg Money at 6am & 8am
      and Nitely
      Business Report at 6:30pm and 7:30pm
      everyday my

      this is a real bad time to buy like JAPAN was.

      • 3 Replies to okdumbass
      • Thought I saw you and your short friends playing
        with this stock. The only reason you are back is to
        try and slam this stock again. Have your fun because
        somewhere along the way you will get bit. What happened to
        BBY? Thought you shorts were heading over there. Never
        did see you take it down. Whats the matter to strong
        of a stock for you guys?

      • <EOM>

      • Protein Design Labs Announces First Quarter 2000

        FREMONT, Calif., April 17 /PRNewswire/ -- The following
        was released today by Protein Design Labs,

        Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news)
        today reported revenues of $15.5 million and net income
        of $770,000 or $0.04 per
        basic and diluted share
        for the three months ended March 31, 2000. These
        results compare with revenues of $8.8 million and a net
        loss of $1.9
        million or ($0.10) per basic and
        diluted share in the 1999 first quarter. Revenues under
        agreements with third parties increased to $12.5
        in the quarter ended March 31, 2000, compared with
        $6.5 million in the 1999 first quarter. Revenues in
        the 2000 first quarter included royalty
        from fourth quarter 1999 sales of three products
        licensed under PDL's antibody humanization patents:
        Synagis� (palivizumab) from
        MedImmune, Inc., Herceptin�
        (trastuzumab) from Genentech, Inc. and Zenapax� (daclizumab)
        from Hoffmann-La Roche Inc. Other components
        revenue included up-front fees paid to PDL pursuant to a
        patent license agreement and a patent rights agreement,
        a portion of up-front fees
        paid to PDL pursuant
        to humanization agreements, sponsored research and
        development funding, and interest income.

7.57-0.02(-0.26%)Jan 23 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.